ABSTRACT:
Background: The oral route is preferred for drug delivery in pediatrics due to its advantages in terms of patient adherence and ease of administration. Risperidone (RIS) is an atypical antipsychotic drug used to manage various psychiatric conditions in children. However, RIS has low aqueous solubility, necessitating the development of an appropriate dosage form to improve its solubility and bioavailability. Aim: This study aimed to formulate and evaluate risperidone chewable jellies as a pediatric dosage form to enhance patient compliance and optimize drug efficacy. Materials and Methods: Solid dispersions of risperidone were prepared using polyvinylpyrrolidone (PVP K30) as a carrier. Four different drug-to-carrier ratios (1:1, 1:2, 1:3, and 1:5) were used, and the formulations were characterized for drug content, production yield, solubility, dissolution, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD). Results: The solubility of risperidone was enhanced with increasing amounts of PVP K30, with the optimum drug-to-polymer ratio of 1:5. The selected formulation showed a 25-fold increase in solubility compared to pure risperidone. FTIR, DSC, PXRD, and SEM analyses confirmed the successful formation of solid dispersions and the amorphous nature of the drug. Conclusion: The selected formulation exhibited improved solubility, suggesting enhanced bioavailability. These chewable jellies have the potential to enhance pediatric patient compliance and serve as a convenient dosage form for the effective management of psychiatric conditions in children.
Cite this article:
Zahraa K. Hussein, Khalid Kadhem Al-Kinani. Formulation and Evaluation of Solid Dispersion Based Pediatric Jellies of Risperidone. Research Journal Pharmacy and Technology. 2025;18(8):3492-0. doi: 10.52711/0974-360X.2025.00503
Cite(Electronic):
Zahraa K. Hussein, Khalid Kadhem Al-Kinani. Formulation and Evaluation of Solid Dispersion Based Pediatric Jellies of Risperidone. Research Journal Pharmacy and Technology. 2025;18(8):3492-0. doi: 10.52711/0974-360X.2025.00503 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-6
REFERENCES:
1. Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019; 11(3): 129.
2. Rowe RC, Sheskey P, Quinn M. Handbook of pharmaceutical excipients: Libros Digitales-Pharmaceutical Press. 2009.
3. Brayfield A. Martindale The complete Drug Reference. Thirty-eighth Edition ed: Pharmaceutical Press. 2014: 1103-7.
4. Mohammed KAB, Ibrahim HK, Ghorab MM. Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone. Drug Delivery. 2016; 23(1): 297-306.
5. Kazi M, Al-Qarni H, Alanazi FK. Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 114: 239-49.
6. Sagheer OM, Ahmed MS, Jwaid MM, Al-Hussaniy HA, Al-Tameemi ZS. The development of molecular docking and molecular dynamics and their application in the field of chemistry and computer simulation. J Med Pharm Allied Sci. 2023; 12(1): 5552–62.
7. Sbârcea L, Tanase I-M, Ledeți A, Cîrcioban D, Vlase G, Barvinschi P, et al. Encapsulation of risperidone by methylated β-cyclodextrins: physicochemical and molecular modeling studies. Molecules. 2020; 25(23): 5694.
8. Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and non-destructive methods of evaluation. International Journal of Pharmaceutics. 2010; 400(1): 49-58.
9. Taher S, Ahmed Z, Al-Kinani K, Alwan Z. Solid Lipid Nanoparticles AS A Promising Approach For Delivery Of Anticancer Agents: Review Article. Military Medical Science Letters. 2021.
10. Hyun S-M, Lee BJ, Abuzar SM, Lee S, Joo Y, Hong S-H, et al. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate. International Journal of Pharmaceutics. 2019; 554: 61-71.
11. ALhassani HR, Al-Khedairy EB. Formulation and In-Vitro Evaluation of Meloxicam Solid Dispersion using Natural Polymers. Iraqi Journal of Pharmaceutical Sciences. 2021; 30(1): 169-78.
12. AlKhalidi MM, Jawad FJ. Enhancement of Aqueous Solubility and Dissolution Rate of Etoricoxib by Solid Dispersion Technique. Iraqi Journal of Pharmaceutical Sciences. 2020; 29(1): 76-87.
13. Soliman MAN, Ibrahim HK, Nour SAE-K. Diacerein solid dispersion loaded tablets for minimization of drug adverse effects: statistical design, formulation, in vitro, and in vivo evaluation. Pharmaceutical Development and Technology. 2021; 26(3): 302-15.
14. Ahmed MS, Reyadh AR, Shareef BQ, Ali AR, Hany AH, Meena AN. Increasing Prevalence of Congenital Hypothyroidism in children with Down Syndrome who have a family history of Thyroid disease. Research Journal of Pharmacy and Technology. 2023; 16(3): 1327-32.
15. Al-Akayleh F, Adwan S, Khanfar M, Idkaidek N, Al-Remawi M. A novel eutectic-based transdermal delivery system for risperidone. AAPS PharmSciTech. 2021; 22(1): 1-11.
16. Krishnamoorthy V, Sen S, PRASAD VPR. Physicochemical characterization of risperidone solid dispersions. ACTA Pharmaceutica Sciencia. 2011; 53(2).
17. Jassim Z, Al-Kinani K, Alwan Z. Preparation and Evaluation of Pharmaceutical Cocrystals for Solubility Enhancement of Dextromethorphan HBr2021.
18. Fitriani L, Fadhila M, Zaini E. Preparation of Efavirenz-PVP K-30 Solid Dispersionby Spray Drying Technique. Research Journal Of Pharmaceutical Biological And Chemical Sciences. 2015; 6(6): 925-30.
19. Sbârcea L, Tănase I-M, Ledeți A, Cîrcioban D, Vlase G, Barvinschi P, et al. Risperidone/randomly methylated β-cyclodextrin inclusion Complex—Compatibility study with pharmaceutical excipients. Molecules. 2021; 26(6): 1690.
20. Sarojini S, Anusha K, Maneesha C, Mufaquam M, Deepika B, Krishna Y. Oral Medicated Jellies–a Review. World Journal of Pharm Res. 2018; 7: 352-65.
21. Jadhav S, Bharkad V, Shinde M, Kadam V, Katkam P. Development and evaluation of oral medicated jelly of ondansetron hydrochloride. World Journal of Pharmacy and Pharmaceutical Sciences. 2017; 6: 1537-49.
22. Mahdi ZH, Maraie NK, Al-Juboori ZA, Najm AS. The Development and Characterization of a New Easily Swallowed Valsartan Oral Jelly. Research Journal of Pharmacy and Technology. 2022; 15(2): 723-8.
23. Gomaa E, Ayoub MM. Vardenafil oral jellies as a potential approach for management of pediatric irritable bowel syndrome. Saudi Pharmaceutical Journal. 2021; 29(9): 955-62.
24. Kadhim¹ ZM, Ali WK. Preparation and evaluation of granisetron chewable pediatric oral jelly. 2019.
25. Yadav C, Tangri S, Yadav R. A review recent advancement in formulation of oral medicated jelly. WJPPS. 2018; 7: 7.
26. Shirse P. Formulation and Evaluation of Oral Medicated gelly Containing Cyclodextrin Inclusion Complexed Water Insoluble Drug-Glimepiride. IJPRD. 2012.
27. Yusof N, Jaswir I, Jamal P, Jami MS. Texture Profile Analysis (TPA) of the jelly dessert prepared from halal gelatin extracted using High Pressure Processing (HPP). Malaysian Journal of Fundamental and Applied Sciences. 2019; 15(4): 604-8.
28. Guiné RP, Correia PM, Reis C, Florença SG. Evaluation of texture in jelly gums incorporating berries and aromatic plants. Open Agriculture. 2020; 5(1): 450-61.
29. Agarwal S, Jhunjhunwala V, Priya G. Fabrication and morphological analysis of gelatin-alginate scaffolds. Research Journal of Pharmacy and Technology. 2018; 11(9): 3816-8.
30. Al-Hussaniy HA, Almajidi YQ, Oraibi AI, Alkarawi AH. Nanoemulsions as medicinal components in insoluble medicines. Pharmacia. 2023; 70(3): 537–47.
31. Dubey M, Sheth Z. Design and development of oral medicated jelly of Palonosetron hydrochloride. Indian Journal of Research. 2015; 4(6): 253-5.
32. Darade AD, Mundada AS. Oral Medicated Jellies As A Emerging Platform For Oral Drug Delivery In Pediatrics. 2021.
33. Al-Kelaby WJ, Al Kaabi ZS, Alhussaniy HA. Histological and histochemical studies of the eye structure of Anas platyrhynchus (Mallard) duck species. Indian Vet. J. 2023; 100(3): 07-15.
34. Cao Z, Wang Z, Gao F, Zhu L, Sha J, Li Y, et al. Thermodynamic analysis and molecular dynamic simulation of the solubility of risperidone (form I) in the pure and binary solvents. Journal of Molecular Liquids. 2022; 359: 119061.
35. Arun R, Elwin J, Jyoti H, Sreerekha S. Formulation and evaluation of Ketoprofen solid dispersion incorporated topical gels. Europ J Biomed and Pharm Sci. 2016; 3(1): 156-64.
36. Abd Sulaiman A, kadhim Abbas H, Al-Samydai AM, Alkufi HK, abdul hadi Kharaba H, Al-hussaniy HA. A Comparative Diagnostic Study for Using the Contrast Agent in Active and Non-Active Multiple Sclerosis by Region of Interest Parameter. Biomedical and Pharmacology Journal. 2023; 16(4): 2531-7.
37. Sharma A, Jain CP. Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci. 2010; 5(1): 49-56.
38. Mohana M, Vijayalakshmi S. Development and characterization of solid dispersion-based orodispersible tablets of cilnidipine. Beni-Suef University Journal of Basic and Applied Sciences. 2022; 11(1): 1-12.
39. Daadoue S, Al-Remawi M, Al-Mawla L, Idkaidek N, Khalid RM, Al-Akayleh F. Deep eutectic liquid as transdermal delivery vehicle of Risperidone. Journal of Molecular Liquids. 2022; 345: 117347.
40. Al-Hussaniy HA, Hassan AF, Oraibi AI, Naji FA, Al-Tameemi ZS. Clinical pharmacogenetics of angiotensin II receptor blockers in Iraq. J Pharm Bioall Sci. 2023; 15(3): 101–6.
41. Król Ż, Malik M, Marycz K, Jarmoluk A. Characteristic of gelatine, carrageenan and sodium alginate hydrosols treated by direct electric current. Polymers. 2016; 8(8): 275.
42. Zhang W, Li G, Xiao C, Chang X, Sun Y, Fan W, et al. Mesoporous Silica Carrier-Based Composites for Taste-Masking of Bitter Drug: Fabrication and Palatability Evaluation. AAPS PharmSciTech. 2022; 23(2): 75.
43. Osorio FA, Bilbao E, Bustos R, Alvarez F. Effects of Concentration, Bloom Degree, and pH on Gelatin Melting and Gelling Temperatures Using Small Amplitude Oscillatory Rheology. International Journal of Food Properties. 2007; 10(4): 841-51.
44. Al-Hussaniy HA, Al-Tameemi ZS, Al-Zubaidi BA, Naji FA, Kilani S. Pharmacological properties of Spirulina species: hepatoprotective, antioxidant and anticancer effects. Farmacia. 2023; 71(4): 670–8.
45. Miyazaki S, Takahashi A, Itoh K, Ishitani M, Dairaku M, Togashi M, et al. Preparation and evaluation of gel formulations for oral sustained delivery to dysphagic patients. Drug Development and Industrial Pharmacy. 2009; 35(7): 780-7.
46. Kumar KV, Vidyadhara S, Babu JR. Favipiravir: Emergent antiviral drug during Covid-19. Medical and Pharmaceutical Journal. 2023; 2(3): 175-80.
47. Hu Y, Liu M, Zhou D, Chen F, Cai Q, Yan X, et al. Gelatine methacrylamide-based multifunctional bilayer hydrogels for accelerating diabetic wound repair. Materials and Design. 2022; 218: 110687.
48. Al-hussaniy H, Kadhim Z. Methicillin-Resistant Staphylococcus aureus and New Delhi Metallo beta-lactamases-types of antibiotic resistance, methods of prevention. Medical and Pharmaceutical Journal. 2022; 1(1): 14-24.
49. Altalebi RR, Al-Hussaniy HA, Al-Tameemi ZS, Al-Zobaidy MA, Albu-Rghaif AH, Alkuraishy HM, Hedeab GM, Azam F, Al-Samydai AM, Naji MA. Non-alcoholic fatty liver disease: relation to juvenile obesity, lipid profile, and hepatic enzymes. Journal of Medicine and Life. 2023; 16(1): 42.
50. Al-Hussaniy HA, Al-Zobaidy MJ. Effects of Mdm2 inhibitors on cellular viability of breast cancer cell lines HP100, MCF7. Bratisl Med J. 2024; 125(10): 627–34.
51. Abdallah MH, El-Horany HE, El-Nahas HM, Ibrahim TM. Tailoring Risperidone-Loaded Glycethosomal In Situ Gels Using Box–Behnken Design for Treatment of Schizophrenia-Induced Rats via Intranasal Route. Pharmaceutics. 2023; 15(11): 2521.
52. Motwani A, Dubey BK, Basedia DK, Patel MK, Shah SK, Thakur VS. Formulation and Characterization of Invasomes Gel of Bacitracin for Effective Treatment of Topical Disease. Saudi J Med Pharm Sci. 2024; 10(12): 895-901.